rs3733591 — SLC2A9 Arg265His

SLC2A9 Arg265His — The Urate Transport Variant That Explains Your Uric Acid Level

Your serum uric acid level is not random — it is tightly regulated by transporters in your kidneys, and the strongest single genetic determinant of that regulation is a gene called SLC2A9. Variants in this gene explain more of the variation in uric acid levels than any other locus in the human genome, and the Arg265His missense variant (rs3733591) is the functional change at the center of this biology.

SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, also called solute carrier family 2 member 9 — despite its name, it transports urate far more efficiently than glucose in the kidney, a high-capacity urate transporter expressed in the proximal tubule of the kidney. It mediates urate reabsorption from the urine back into the bloodstream (basolateral isoform) and urate secretion into the tubular lumen (apical isoform). Variants in SLC2A9 explain up to 5.3% of all variance in serum uric acid concentrations — larger than any other single genetic locus.

The Mechanism

The Arg265His variant changes a positively charged arginine residue to a neutral histidine at position 265 of the SLC2A9 short isoform (position 294 in the long isoform). The ancestral Arg265 allele (C on the plus strand) is associated with modestly less efficient urate transport, while the derived His265 allele (T) appears to facilitate more effective urate clearance.

The effect is dose-dependent and additive: each copy of the Arg265 (C) allele adds approximately 0.65 mg/dL to serum uric acid. In a study of 250 healthy Korean males, mean uric acid was 5.42 mg/dL in TT carriers (His/His), 6.12 mg/dL in CT carriers, and 6.74 mg/dL in CC carriers — a 1.32 mg/dL spread driven entirely by genotype (Park et al., 2022)²² (Park et al., 2022). This puts CC carriers in the range where hyperuricemia (>7 mg/dL in men) becomes plausible even without dietary provocation.

SLC2A9 has two isoforms with different membrane localizations: the long isoform (GLUT9a) is expressed on the basolateral face of proximal tubule cells and mediates urate reabsorption from the interstitium, while the short isoform (GLUT9b) is on the apical face and handles secretion. Both isoforms are affected by the Arg265His substitution, though the net clinical effect is elevated reabsorption and reduced net urinary urate excretion.

The Evidence

Original GWAS discovery: The SLC2A9 locus was identified as the strongest genetic determinant of serum uric acid in genome-wide association scanning of a Croatian population, subsequently replicated in UK and German cohorts (Döring et al., 2008)³³ (Döring et al., 2008). Variants at this locus collectively explained 1.7–5.3% of uric acid variance, a remarkably large effect for a common variant.

Gout associations in Asian populations: In 109 Han Chinese gout cases and 191 controls, the Arg265 (C) allele was significantly overrepresented in gout (p=0.0012) and particularly in tophaceous gout (OR 2.05–2.15, p=0.0044). The effect replicated in Solomon Islanders for tophaceous gout (p=0.0184), with the C allele explaining 3.68% and 5.98% of uric acid variability in Chinese and Solomon Island subjects respectively (Tu et al., 2010)⁴⁴ (Tu et al., 2010).

Population specificity: The association with gout is strongest in populations where the Arg265 (C) allele is rare enough to create meaningful variation — East Asian populations (Han Chinese C freq ~0.32) rather than European populations (C freq ~0.81). In Māori, the C allele conferred an OR of 2.21 for tophaceous gout (p=0.01), with no effect on non-tophaceous gout. No significant association was found in Caucasians, consistent with the high C allele frequency leaving little power to detect an effect (Hollis-Moffatt et al., 2011)⁵⁵ (Hollis-Moffatt et al., 2011).

Taiwan Biobank (large-scale validation): In 73,558 subjects including 2,709 gout cases, the TC+CC genotype was associated with gout (OR 1.15, 95% CI 1.06–1.25). The effect was significant in men (OR 1.16) but not women, and was amplified by metabolic syndrome (OR 1.39 for TC+CC with MetS vs reference). This demonstrates that the variant's effect on clinical gout requires co-factors — it acts as a risk amplifier, not a deterministic cause.

Sex-specific effects: SLC2A9 variants overall have a greater effect on serum urate in women (explaining ~6% of variance) than in men (~2%), believed to reflect an interaction with estrogen, which independently increases renal urate excretion. Pre-menopausal women carrying risk alleles may have attenuated effects from estrogen's uricosuric action, while post-menopausal women lose this protection and become more susceptible to SLC2A9-driven hyperuricemia.

Additive interaction with ABCG2 rs2231142: SLC2A9 rs3733591 and ABCG2 rs2231142 act through independent mechanisms in the urate transport pathway and show additive effects on serum uric acid. In the Korean study, the combined diplotype CC/AG (high-risk at both loci) reached mean uric acid of 7.15 mg/dL — above the clinical threshold for hyperuricemia — while the low-risk diplotype (TT/GG) had 5.16 mg/dL. The two loci together explained substantially more variance than either alone.

Practical Actions

The Arg265His variant informs uric acid management through two mechanisms: establishing baseline risk and calibrating dietary and lifestyle interventions. Elevated serum uric acid responds well to modifiable factors, so genetic predisposition is not destiny.

Effective dietary levers: reduce purine-rich foods (organ meats, red meat, shellfish, anchovies), minimize alcohol especially beer (fructose in alcohol competes with urate for renal excretion), replace sugar-sweetened beverages with water, and maintain adequate hydration (2–3 L/day to support renal urate clearance). Low-fat dairy consumption is associated with reduced gout risk and may be specifically beneficial for carriers.

Serum uric acid should be the monitoring target. A level below 6 mg/dL minimizes crystal formation risk; below 5 mg/dL is recommended if tophi are present. CC carriers, particularly those with metabolic syndrome, elevated BMI, or heavy alcohol use, have the strongest indication for routine uric acid monitoring.

If urate-lowering therapy is needed, allopurinol (xanthine oxidase inhibitor) and febuxostat are both effective; the choice of agent is not specifically genotype-dependent for SLC2A9, unlike for ABCG2 variants. However, CC carriers with concurrent ABCG2 Q141K variants may require higher allopurinol doses.

Interactions

SLC2A9 and ABCG2 (rs2231142): Both genes mediate urate transport and their risk alleles act additively. ABCG2 Q141K reduces intestinal urate secretion; SLC2A9 Arg265His reduces renal urate clearance. Together they produce substantially higher serum urate than either alone. Individuals carrying risk alleles at both loci should be treated as having compounded risk and monitored proactively.

Sex and menopausal status: The SLC2A9 effect is modulated by estrogen, making the Arg265His variant particularly relevant in post-menopausal women who lose estrogen's uricosuric effect and become more vulnerable to genetically elevated uric acid.

Metabolic syndrome: The Taiwan Biobank study demonstrates a significant gene-environment interaction between rs3733591 and metabolic syndrome. Insulin resistance impairs renal urate excretion independently of SLC2A9 genotype, and the combination creates substantially elevated gout risk (OR 1.39) even compared to genetic risk alone.